Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-time Adjusted Survival of Patients With Compensated Viral Cirrhosis.
Fiche publication
Date publication
mai 2018
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre, Pr DI MARTINO Vincent
Tous les auteurs :
Costentin C, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P,
Lien Pubmed
Résumé
Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus (HCV)- or HBV-associated compensated cirrhosis who developed HCC.
Mots clés
Curative Treatment, Early Detection, Liver Cancer, Screening
Référence
Gastroenterology. 2018 May 2;: